Abstract:Abstract Cancer is the second leading cause of death worldwide. Although multiple new cancer treatments have emerged in recent years, drug therapy, mainly comprising chemotherapy, targeted therapy, and immunotherapy, remains the most common approach. The multidrug resistance (MDR) of cancer cells to various treatments remains a challenge. Scientists have always focused on the acquired drug resistance mechanisms of tumor cells themselves. However, recent evidence shows that the tumor microenvironment (TME) plays a critical role in regulating tumor cell progression, metastasis, immune escape, and drug resistance. In the TME, interactions between cancer cells and non-malignant cells often modify the TME and facilitate drug resistance. Therefore, elucidating this complex interaction mechanism is essential for the development of effective treatments. This review focuses on the role of the TME in promoting chemoresistance in tumor cells through the following mechanisms: (i) inhibiting the immune clearance of tumor cells and facilitating immune escape responses; (ii) stimulating the release of soluble paracrine factors to enhance tumor survival and growth; (iii) promoting survival and altering drug delivery through metabolic reprogramming; (iv) obstructing drug absorption by inducing changes in stomatal cells and blood vessels surrounding the tumor; and (v) inducing the cancer stem cell phenotype. This review also addresses a clinical treatment strategy for targeting the TME, providing insights and a basis for reversing multidrug resistance.

What problem does this paper attempt to address?

The paper mainly discusses the crucial role of the tumor microenvironment (TME) in multidrug resistance (MDR) in cancer. TME consists of tumor cells, immune cells, stromal cells, and blood vessels, which promote chemotherapy resistance through various mechanisms: 1. Immune clearance suppression: Immunosuppressive cells in TME, such as tumor-associated macrophages (TAMs), can inhibit immune cells from attacking tumor cells. 2. Growth factor secretion: TAMs and other cells release growth factors to promote the survival and proliferation of tumor cells. 3. Metabolic reprogramming: Altering the metabolic pathways of tumor cells enhances their survival ability and influences drug delivery. 4. Modifying surrounding cells and blood vessels of the tumor: This affects drug absorption, such as by altering the structure of pore cells and blood vessels. 5. Induction of cancer stem cell phenotype: This makes tumor cells more resistant. The paper also discusses how immunosuppressive cells in TME, such as regulatory T cells and myeloid-derived suppressor cells, promote resistance by producing inhibitory molecules and interfering with immune responses. In addition, the metabolic changes, hypoxic conditions, and acidic environment in TME are also associated with drug resistance. Finally, the paper proposes that therapeutic strategies targeting TME may reverse MDR and provides examples of clinical trials, emphasizing the importance of understanding the role of TME in promoting MDR for the development of effective treatments.

The tumor microenvironment: a key player in multidrug resistance in cancer